Stock Financial Ratios, Dividends, Split History

ITRI / Itron, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,375.63
Enterprise Value ($M)3,012.33
Book Value ($M)685.97
Book Value / Share17.50
Price / Book3.46
NCAV ($M)-1,099.29
NCAV / Share-28.04
Price / NCAV-2.14
Share Statistics
Common Stock Shares Outstanding 38,771,000
Weighted Average Number Of Diluted Shares Outstanding 39,387,000
Common Shares Outstanding 38,784,060
Weighted Average Number Of Shares Outstanding Basic 38,655,000
Preferred Stock Shares Outstanding 0
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.05
Return on Assets (ROA)0.04
Return on Equity (ROE)0.10
Balance Sheet (mrq) ($M)
Quick Ratio1.13
Current Ratio1.46
Income Statement (mra) ($M)
Sales Revenue Goods Net1,813,925,000.00
Sales Revenue Net2,018,197,000.00
Sales Revenue Services Net204,272,000.00
Operating Income151.43
Net Income60.25
Earnings Per Share Basic1.48
Earnings Per Share Diluted1.45
Cash Flow Statement (mra) ($M)
Cash From Operations191.35
Cash from Investing-148.18
Cash from Financing191.35
Identifiers and Descriptors
Central Index Key (CIK)780571
Related CUSIPS
465741906 465741956

Split History

Stock splits are used by Itron, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Landis+Gyr: Global Leader In Smart Meters

2018-06-19 seekingalpha
Swiss-based Landis+Gyr (OTCPK:LDGYY) is the largest manufacturer of smart grid monitors in the world. The company was taken public last July as Toshiba needed to liquidate. About half of the United States' energy users do not have smart monitors which leaves room for growth over the next few years.

Itron (ITRI) Down 12.7% Since Earnings Report: Can It Rebound?

2018-06-13 zacks
It has been about a month since the last earnings report for Itron, Inc. (ITRI - Free Report) . Shares have lost about 12.7% in that time frame. (35-0)

Stocks To Watch: Eyes On Apple's WWDC, SCOTUS And D.C.

2018-06-02 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (932-4)

Itron's Smart Grid Solution to Widen JPS' Metering Services

2018-05-23 zacks
Itron, Inc. (ITRI - Free Report) has signed a contract with Jamaica Public Service Company (JPS) to unify 670,000 electric meters of the latter through Itron's smart grid network. Jamaica's nationwide smart-grid deployment will extend the utility's smart-meter automation benefits and enhance post-storm restorations. JPS, which serves more than 600,000 customers, has been transforming its lighting and electricity services for the past few years. (39-0)

Itron (ITRI) Inks Deal With NWL to Implement DTM Solution

2018-05-16 zacks
Itron, Inc. (ITRI - Free Report) has signed a contract with Network Waitaki Limited (NWL) to deploy the Distribution Transformer Monitoring (DTM) solution of the former. Financial details of the deal remain undisclosed. NWL is an electricity lines company which distributes electricity from the national grid to consumers' properties in New Zealand. Per the contract, NWL will utilize Itron’s cloud-based Software-as-a-Service (SaaS) applications for operating the DTM solution. (22-0)

CUSIP: 465741106